RT Journal Article
SR Electronic
T1 Curative Resection After Gemcitabine, Cisplatin and S-1 Chemotherapy for Initially Unresectable Biliary Duct Cancer: A Case Report
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4203
OP 4206
VO 35
IS 7
A1 KENEI FURUKAWA
A1 TADASHI UWAGAWA
A1 TARO SAKAMOTO
A1 HIROAKI SHIBA
A1 JUN TSUTSUMI
A1 KATSUHIKO YANAGA
YR 2015
UL http://ar.iiarjournals.org/content/35/7/4203.abstract
AB A 68-year-old woman was diagnosed with unresectable upper bile duct cancer with suspected invasion of the right hepatic artery and para-aortic lymph node metastasis (T4N3M0, stage IVb). She underwent plastic stent placement for obstructive jaundice and enrolled in our phase I study for unresectable biliary tract cancer consisting of cisplatin (25 mg/m2 i.v. for 120 min) followed by gemcitabine (1,000 mg/m2 i.v. for 30 min) on days 1 and 8, and oral S-1 on alternate days. After 8 courses of neoadjuvant chemotherapy without adverse effects, computed tomography showed near-complete disappearance of the tumor of the upper bile duct and of swollen lymph nodes. She then underwent sub-total stomach-preserving pancreatico duodenectomy and lymph node dissection. The pathological stage was pT1N0M0, stage I. The patient made a satisfactory recovery, was discharged 29 days after operation, and remains free of disease at 3 months after the operation under adjuvant chemotherapy using S-1.